ArticleJournal of cancer research and clinical oncology2022

HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer.

Wenbai Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.